DDDanny Dvir

Danny Dvir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Danny Dvir has a total of 619 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Echocardiographic Predictors of Underutilization of Mitral Valve Intervention in Patients with Significant Mitral Regurgitation

    by Ilia Davarashvili, Danny Dvir

    Background: Mitral regurgitation (MR) is one of the most common valvular heart diseases and is associated with substantial morbidity and mortality if left untreated. Despite guideline recommendations, many patients with significant MR do not undergo surgical or transcatheter mitral valve intervention. We aimed to identify the clinical and echocardiographic characteristics associated with mitral valve intervention. Methods: We retrospectively analyzed 1,637 consecutive patients with moderate-to-severe or severe MR evaluated at Shaare Zedek Medical Center between December 2016 and December 2021. Patients were categorized into an intervention group (n = 191) and a conservatively managed group (n = 1,446). Clinical and echocardiographic characteristics were compared using univariable and multivariable logistic regression analyses. Results: Among 1,637 patients, only 191 (11.7%) underwent mitral valve intervention. Patients receiving intervention were younger (72.8 ± 12.9 vs. 76.5 ± 14.2 years; p = 0.001), more frequently male (57.6% vs. 48.0%; p = 0.013), and more commonly of Arab ethnicity (22.5% vs. 13.1%; p < 0.001). Severe MR (68.6% vs. 40.1%; p = 0.0004) and prosthetic mitral valve (6.8% vs. 2.3%; p = 0.0004) were more common among treated patients, whereas hypertension, advanced chronic kidney disease, and previous myocardial infarction were less common. Independent predictors of intervention were younger age (OR 0.98, 95% CI 0.97–0.99; p = 0.035), Arab ethnicity (OR 2.02, 95% CI 1.24–3.29; p = 0.005), and severe MR (OR 2.87, 95% CI 1.88–4.35; p < 0.001). Conclusions: Only a small proportion of patients with significant MR underwent mitral valve intervention. Older patients and those with ischemic or renal comorbidities were more likely to be managed conservatively. Earlier referral to dedicated Heart Valve Teams may improve access to guideline-directed treatment.

  • Open Access

    First-in-Human Mechanical Leaflet Modification of Native Aortic Stenosis During TAVR

    by Danny Dvir, Amjad Abu Salman, Philippe Taieb, Shemy Carasso, Rami Jubeh, Arik Wolak, Elias Hellou, Michael Glikson, Anna Turyan

  • Open Access

    First Large Comprehensive Core-Laboratory Evaluation of Implantation Depth and Clinical Outcomes in TAVR: Final Global Results from the Optimize PRO Prospective Study

    by Danny Dvir, Hasan A. Jilaihawi, Douglas Fraser, Josep Rodes-Cabau, Tamim Nazif, Suneet Mittal, Kendra J. Grubb, Hemal Gada, Emmanuel Teiger, Lang Lin, et al.

  • Open Access

    First-in-Human Transcatheter Aortic Root Tricuspidization of Stenotic Bicuspid Valves

    by Danny Dvir, Hasan Jilaihawi, Ikki Komatsu, Anna Turyan, Rami Jubeh, Phillipe Taieb, Vivek Patel, Kazuki Suruga, Creighton Don


  • Open Access

    First Report of Anchoring Via Trans-Leaflet Apposition Stent (ATLAS)

    by Danny Dvir, Anna Turyan, Amjad Abu Salman, Rami Jubeh, Daniel Fink, Arik Wolak, Raffi Hitter, Elchanan Bruckheimer, Michael Glikson, Philippe Taieb


  • Open Access

    Simultaneous Cardioflow Optimisation to facilitate haemodynamic recovery after rapid ventricular pacing during transcatheter aortic valve implantation: a case series

    by Rami Jubeh, Elad Asher, Danny Dvir, Michael Glikson, Sharon Bruoha

    Background: ‘Simultaneous CardioFlow optimization’ represents an innovative technique that effectively enhances post-pacing haemodynamic recovery during transcatheter aortic valve replacement. This technique was applied in two high-risk patients presenting with severe left main trunk stenosis with concomitant severe aortic stenosis (AS) and left ventricular dysfunction (LVD). Case summary: An 86-year-old and a 96-year-old patient were admitted with myocardial infarction. Angiography revealed severe left main trunk stenosis, while echocardiography demonstrated significant LVD and severe AS. Both cases were evaluated by the institutional multidisciplinary heart team. Considering the high surgical risk, a percutaneous management strategy was contemplated. Discussion: We postulated that performing left main trunk balloon angioplasty during rapid ventricular pacing would be better tolerated, compared with conventional balloon angioplasty, given the low coronary perfusion pressure at this stage. Additionally, coronary balloon angioplasty is expected to enhance coronary flow in the immediate post-pacing period, thus facilitating haemodynamic recovery. Both patients exhibited prompt improvement in hemodynamics following rapid ventricular pacing and had uncomplicated hospital stays. In patients with significant left main trunk stenosis accompanied by severe AS and concomitant left ventricular dysfunction, ‘simultaneous CardioFlow optimisation’ facilitates post-pacing haemodynamic recovery.

  • Open Access

    Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study

    by Danny Dvir, Didier Tchétché, Martin B Leon, Philippe Généreux, Benjamin Seguy, Raj Makkar, Philippe Pibarot, Hemal Gada, Tamim Nazif, David Hildick-Smith, et al.

    This trial sought to assess the safety and efficacy of ShortCut, the first dedicated leaflet modification device, prior to transcatheter aortic valve implantation (TAVI) in patients at risk for coronary artery obstruction. This pivotal prospective study enrolled patients with failed bioprosthetic aortic valves scheduled to undergo TAVI and were at risk for coronary artery obstruction. The primary safety endpoint was procedure-related mortality or stroke at discharge or 7 days, and the primary efficacy endpoint was per-patient leaflet splitting success. Independent angiographic, echocardiographic, and computed tomography core laboratories assessed all images. Safety events were adjudicated by a clinical events committee and data safety monitoring board. Sixty eligible patients were treated (77.0 ± 9.6 years, 70% female, 96.7% failed surgical bioprosthetic valves, 63.3% single splitting and 36.7% dual splitting) at 22 clinical sites. Successful leaflet splitting was achieved in all [100%; 95% confidence interval (CI) 94%–100.0%, P < .001] patients. Procedure time, including imaging confirmation of leaflet splitting, was 30.6 ± 17.9 min. Freedom from the primary safety endpoint was achieved in 59 [98.3%; 95% CI (91.1%–100%)] patients, with no mortality and one (1.7%) disabling stroke. At 30 days, freedom from coronary obstruction was 95% (95% CI 86.1%–99.0%). Within 90 days, freedom from mortality was 95% [95% CI (86.1%–99.0%)], without any cardiovascular deaths. Modification of failed bioprosthetic aortic valve leaflets using ShortCut was safe, achieved successful leaflet splitting in all patients, and was associated with favourable clinical outcomes in patients at risk for coronary obstruction undergoing TAVI. This pivotal prospective, multicentre study presents favourable clinical outcomes of ShortCut, the first dedicated leaflet modification device, prior to transcatheter aortic valve implantation (TAVI) in patients scheduled to undergo TAVI and at risk for coronary artery obstruction.


  • Open Access

    Culprit Lesion Coronary Intervention Before Complete Angiography in ST-Elevation Myocardial Infarction

    by Nir Levi, Rafael Wolff, Rami Jubeh, Mony Shuvy, Yoed Steinmetz, Nimrod Perel, Tomer Maller, Itshak Amsalem, Rafael Hitter, Elad Asher, et al.

    Importance: Rapid reperfusion during primary percutaneous coronary intervention (PCI) is associated with improved outcomes among patients with ST-elevation myocardial infarction (STEMI). Although attempts at reducing the time from STEMI diagnosis to arrival at the catheterization laboratory have been widely investigated, intraprocedural strategies aimed at reducing the time to reperfusion are lacking.Objective: To evaluate the effect of culprit lesion PCI before complete diagnostic coronary angiography (CAG) vs complete CAG followed by culprit lesion PCI on reperfusion times among patients with STEMI.Design, Setting, and Participants: This open-label, prospective, randomized clinical trial was conducted between April 1, 2021, and August 31, 2022, among patients admitted to a tertiary center in Jerusalem, Israel, with a diagnosis of STEMI undergoing primary PCI. All patients were followed up for 1 year. Analysis was on an intention-to-treat basis.Intervention: Patients were randomized in a 1:1 ratio to undergo either culprit lesion PCI before complete CAG or complete CAG followed by culprit lesion PCI.Main Outcomes and Measures: A needle-to-balloon time of 10 minutes or less.Results: A total of 216 patients were randomized, with 184 patients (mean [SD] age, 62.9 [12.2] years; 155 men [84.2%]) included in the final intention-to-treat analysis; 90 patients (48.9%) were randomized to undergo culprit lesion PCI before CAG, and 94 (51.1%) were randomized to undergo to CAG followed by PCI. Patients who underwent culprit lesion PCI before complete CAG had a shorter mean (SD) needle-to-balloon time (11.4 [5.9] vs 17.3 [13.3] minutes; P < .001). The primary outcome of a needle-to-balloon time of 10 minutes or less was achieved for 51.1% of patients (46 of 90) who underwent culprit lesion PCI before CAG and for 19.1% of patients (18 of 94) who underwent complete CAG followed by culprit lesion PCI (odds ratio, 4.4 [95% CI, 2.2-9.1]; P < .001). Rates of adverse events were similar between groups. In a subgroup analysis, the effect of culprit lesion PCI before complete CAG on the primary outcome was consistent. There were no differences in rates of in-hospital, 30-day, and 1-year all-cause mortality.Conclusions and Relevance: In this randomized clinical trial of patients with STEMI, culprit lesion PCI before complete CAG resulted in shorter reperfusion times. Larger trials are needed to validate these results and to evaluate the effect on clinical outcomes.Trial Registration: ClinicalTrials.gov Identifier: NCT05415085


  • Clinical and Hemodynamic Outcomes of Balloon-Expandable Mitral Valve-in-Valve Positioning and Asymmetric Deployment

    by Matheus Simonato, Brian K. Whisenant, Axel Unbehaun, Jörg Kempfert, Henrique B. Ribeiro, Ran Kornowski, Magdalena Erlebach, Sabine Bleiziffer, Stephan Windecker, Thomas Pilgrim, et al.